Neurocrine Biosciences | NBIX - Cost Of Sales

Stock Price
141.25
Daily Change
3.32 2.41%
Monthly
0.45%
Yearly
15.19%
Q1 Forecast
131.87

Neurocrine Biosciences reported $264M in Cost of Sales for its fiscal quarter ending in September of 2025.





Cost Of Sales Change Date
AbbVie USD 4.55B 757M Dec/2025
Acadia Pharmaceuticals USD 21.65M 913K Sep/2025
Agios Pharmaceuticals USD 1.68M 22K Sep/2025
ALKERMES USD 51.59M 2.13M Sep/2025
Alnylam Pharmaceuticals USD 200.15M 57.2M Sep/2025
Amgen USD 1.79B 128M Dec/2025
Biogen USD 810.1M 205.1M Sep/2025
BioMarin Pharmaceutical USD 144.93M 10M Sep/2025
Cytokinetics USD 112.55M 12.71M Jun/2025
Dynavax Technologies USD 14.4M 368K Sep/2025
Exelixis USD 18.57M 896K Sep/2025
Gilead Sciences USD 1.57B 68M Sep/2025
Halozyme Therapeutics USD 73M 8.88M Sep/2025
Incyte USD 99M 20.23M Sep/2025
Ionis Pharmaceuticals USD 2.34M 1.81M Sep/2025
Neurocrine Biosciences USD 264M 252.7M Sep/2025
Pfizer USD 6.29B 2.12B Dec/2025
Prothena USD 28.94M 11.58M Sep/2025
Regeneron Pharmaceuticals USD 584.6M 63M Dec/2025
Repligen USD 88.29M 2.93M Sep/2025
Sarepta Therapeutics USD 151.45M 1.77M Sep/2025
Teva Pharmaceutical Industries USD 2.06B 120M Dec/2025
Ultragenyx Pharmaceutical USD 27.99M 4.99M Sep/2025
Vertex Pharmaceuticals USD 414.8M 7.3M Sep/2025